Clinical trials: Respiratory Exacerbation
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Acute Asthma
Budesonide Inhalation Suspension for Acute Asthma in Children
The purpose of this study is to determine whether the addition of budesonide inhalation suspension (BIS) to the standard therapy of albuterol, ipratropium bromide, and systemic corticosteroids (SCS) for moderate to severe asthma…
- Conditions
- Asthma, Acute Asthma, Reactive Airway Exacerbation
- Trial name
- NCT00393367
- Testing
- Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Children's Hospital of Philadelphia
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
Asthma
Fall Epidemic Viral Pediatric Study
Study ADA113872 is an exploratory 16-week multi-centre, randomized, double-blind, parallel group study in pediatric subjects, 4 to 11 years of age, with a history of seasonal asthma exacerbation(s).
- Trial name
- NCT01192178
- Testing
- FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
- Where
- 38 sites in United States
- Volunteers
- 339 people
- Sponsor
- GlaxoSmithKline
Asthma
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation
The purpose of this study is to evaluate the effectiveness of nebulized magnesium sulfate as a vehicle for albuterol in children with moderate to severe asthma exacerbation.
- Trial name
- NCT01515995
- Testing
- Nebulized magnesium sulfate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Chronic Obstructive Pulmonary Disease
Smart Telehealth Exercise Intervention to Reduce COPD Readmissions
This is a prospective randomized controlled study to test the hypothesis that neuromuscular electrical stimulation (NMES) and remote pulmonary rehabilitation at home offered via a smart technology, called Smart TeleHealth…
- Trial name
- NCT03089853
- Testing
- Neuromuscular electrical stimulation (NMES)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
Respiratory Tract Infections
Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine
To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in…
- Trial name
- KLARAINE (NCT01095978)
- Testing
- Clarithromycin (Klacid SR)
- Where
- 126 sites in Ukraine
- Volunteers
- 2,822 people
- Sponsor
- Abbott
Asthma
Asthma Exacerbation Study
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
- Trial name
- NCT01086384
- Testing
- Fluticasone Furoate/GW642444, Fluticasone furoate
- Where
- 183 sites in United States, Argentina and 9 more
- Volunteers
- 2,020 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease With Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation
Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects
The morbidity rate of Chronic Obstructive Pulmonary Disease (COPD) is increasing year by year. It is predicted to be the third leading cause of death worldwide in 2030.
- Conditions
- Chronic Obstructive Pulmonary Disease With Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation, Chronic Pulmonary Disease
- Trial name
- NCT04828837
- Testing
- bubble PEP
- Where
- Taiwan
- Volunteers
- 57 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Cystic Fibrosis
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older.
- Trial name
- NCT03451045
- Testing
- Lenabasum 20 mg, Lenabasum 5 mg
- Where
- 105 sites in United States, Austria and 19 more
- Volunteers
- 447 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
Asthma
Exacerbation Risk in Asthma
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
- Trial name
- NCT05501639
- Testing
- tiotropium, long-acting β2-agonists (LABA), inhaled corticosteroids (ICS)
- Where
- United States
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Asthma
Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation
Project Aim: To determine if intramuscular epinephrine is an effective adjunct to inhaled bronchodilators (β2 agonists) for children with severe asthma exacerbation.
- Trial name
- NCT01705964
- Testing
- IM epinephrine 1:1000, No intervention
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Louisville
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks.
- Trial name
- STRIVE-IPF (NCT03286556)
- Testing
- Autoantibody Reductive Therapy, Treatment as Usual (TAU)
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Disease, Chronic Obstructive
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
- Trial name
- NCT05241288
- Testing
- Albuterol eMDPI DS
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill